Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.